
Company valuation, historical trends, and peer comparisons.
According to Exelixis, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 17.53B. This represents a change of 37.61% compared to the average of 12.74B of the last 4 quarters.
The mean historical Enterprise Value of Exelixis, Inc. over the last ten years is 6.80B. The current 17.53B Enterprise Value has changed 157.68% with respect to the historical average. Over the past ten years (40 quarters), EXEL's Enterprise Value was at its highest in in the October 2026 quarter at 14.27B. The Enterprise Value was at its lowest in in the December 2016 quarter at 4.33B.
Average
6.80B
Median
5.74B
Minimum
3.77B
Maximum
11.53B
Discovering the peaks and valleys of Exelixis, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 165.72%
Maximum Annual Enterprise Value = 11.53B
Minimum Annual Increase = -36.51%
Minimum Annual Enterprise Value = 3.77B
| Year | Enterprise Value | Change |
|---|---|---|
| 2026 | 11.53B | 17.30% |
| 2025 | 9.83B | 29.98% |
| 2023 | 7.56B | 55.98% |
| 2022 | 4.85B | -6.08% |
| 2021 | 5.16B | -12.79% |
| 2020 | 5.92B | 15.66% |
| 2019 | 5.12B | -7.98% |
| 2018 | 5.56B | -36.51% |
| 2017 | 8.76B | 132.09% |
| 2016 | 3.77B | 165.72% |
The current Enterprise Value of Exelixis, Inc. (EXEL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
9.64B
5-year avg
7.78B
10-year avg
6.80B
Exelixis, Inc.’s Enterprise Value is less than Incyte Corporation (20.95B), greater than Rigel Pharmaceuticals, Inc. (915.55M), greater than HUTCHMED (China) Limited (2.28B), less than Genmab A/S (37.85B), less than Revolution Medicines, Inc. (40.27B), greater than Syndax Pharmaceuticals, Inc. (1.42B), greater than Curis, Inc. (-3296530.00), greater than Ipsen S.A. (11.96B), less than Astellas Pharma Inc. (4.95T), less than AstraZeneca PLC (314.22B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 20.95B | $24.19B | |
| 915.55M | $936.41M | |
| 2.28B | $2.34B | |
| 37.85B | $33.96B | |
| 40.27B | $40.44B | |
| 1.42B | $1.17B | |
| -3296530.00 | $1.28M | |
| 11.96B | $56.46B | |
| 4.95T | $29.10B | |
| 314.22B | $288.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Exelixis, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Exelixis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Exelixis, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Exelixis, Inc. (EXEL)?
What is the 3-year average Enterprise Value for Exelixis, Inc. (EXEL)?
What is the 5-year average Enterprise Value for Exelixis, Inc. (EXEL)?
How does the current Enterprise Value for Exelixis, Inc. (EXEL) compare to its historical average?